Serena Williams wants to be transparent and is opening up about her fitness journey, revealing she's taking a GLP-1 ...

L’Agence nationale de sécurité du médicament et des produits de santé a décidé d’élargir la prescription de ces traitements, ...

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Lexaria Bioscience Corp. a publié une mise à jour concernant le secteur du peptide-1 de type glucagon et de l'obésité. Le ...

The metabolism of GLP-1 in the body is extremely rapid and the peptide gets inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), even before leaving the gut. 3 Glucagon is a key hormone in ...

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%.

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Glucagon-like peptide-1 (7–36) amide (GLP-1) is a gut hormone released from the L cells in the mucosa of the jejunum, ileum and colon in response to the ingestion of carbohydrate and fat.

The glucagon-like peptide 1 (GLP-1) agonist market size was valued at USD 10.8 Billion in 2023 and is expected to reach a market size of USD 21.2 Billion by 2032 at a CAGR of 7.8%.Fort Collins ...

Novel Glucagon like peptide-1 (GLP-1) drugs were designed and industrial prepared by researchers from Hefei Institutes of Physical Science, Chinese Academy of Sciences Through molecular design ...